about
Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreportingCharacteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.Case series: inhaled coral vapor--toxicity in a tank.Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018.Unintentional methadone and buprenorphine exposures in children: Developing prevention messages.Childhood lead poisoning from paint chips: a continuing problem.Notes from the Field: Cardiac Dysrhythmias After Loperamide Abuse - New York, 2008-2016.Thyroid storm after pediatric levothyroxine ingestion.IV versus oral N-acetylcysteine.A question of the clinical relevance of determining thrombomodulin level while receiving anticoagulant therapy.Prediction rule in opioid overdose.Histamine poisoning from seafood.Acute tacrolimus overdose without significant toxicity.Use of pharmaceutical promotility agents in the treatment of body packers.Comparing dexmedetomidine with midazolam for sedation of patients in the ICU.Cocaine and aneurysms.Penile angioedema associated with the use of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers.Body weight and response to vitamin K administration.Letter in response to: therapeutic hypothermia after cardiac arrest caused by self-inflicted intoxication: a multicenter retrospective cohort study.In Response to "The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery from Copperhead Snake Envenomation".Analysis of K2 products sold as incense.Routine biological tests in self-poisoning patients: results from an observational prospective multicenter study.Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations.Letter in response to "Efficiency of acidemia correction on intermittent versus continuous hemodialysis in acute methanol poisoning".The Use of 3- and 4-Factor Prothrombin Complex Concentrate in Patients With Elevated INR.Letter to the editor in response to: The correlation between prolonged corrected QT interval with the frequency of respiratory arrest, endotracheal intubation, and mortality in acute methadone overdose.Low dose intramuscular methadone for acute mild to moderate opioid withdrawal syndrome.Poison control center experience with tianeptine: an unregulated pharmaceutical product with potential for abuseMassive Necrosis of the Gastrointestinal Tract after Ingestion of Hydrochloric AcidA Letter to the Editor: carbon monoxide poisoning deaths in the United States, 1999 to 2012The work lifeSymptom-triggered therapy for alcohol withdrawal syndrome in medical inpatientsHemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and salineA golden rule or a golden guide?Clinical complexity of carbon monoxide poisoningPredicting delirium tremensLactate and carbon monoxide poisoning: More questions regarding its prognostic roleTroponin elevations and organophosphate poisoning: direct cardiac injury or demand ischemia?The synthetic cannabinoid withdrawal syndromeResponse to "evaluation of dabigatran exposures reported to poison control centers"
P50
Q28607852-CB4F8390-677F-4BE8-B975-FB85B63BA3E0Q36619477-799256B3-E093-4503-95A5-DD8B22E73D1DQ37165410-6493ED17-C30C-42EB-BCF7-460629C31091Q38383364-FBBF734E-C3B9-44A8-B4DB-1A8F6893D388Q38908543-FCB60711-6E08-45D8-B8AA-49BAA4B21CBFQ39637246-CF8F2EF6-17C3-46FC-A7D5-2E9C7EE6CF92Q40472087-0907148A-493D-495D-9F23-E1E448739D3FQ42965470-D5EEFACD-960A-440F-88BF-98306F33B118Q43234951-349C6290-6DC5-4A1D-A93A-FBA1536704E8Q43236711-2ABCBAE0-E147-472E-9405-CFAC0145F5A0Q43558238-CE5BA38A-A4C2-4B69-A627-6949651A8B4AQ43643156-E8137162-30DE-477F-BCA6-8F7440E12533Q44069730-AADA3F50-834D-49BD-84C3-BAF5E8F21D3CQ44629128-B597FD63-8DCA-4555-B07F-3AC483A8422CQ44784987-D48A2B66-C2EF-45D2-92D5-8F6B71623F71Q46339065-72D661AB-EA67-4726-ABD1-AF5268C27546Q46748025-4B93B2B1-C5DA-49B3-B5A8-41D948F57D6AQ47193365-91B58C7A-2F22-43EE-8EFB-0EF7C35146E7Q47284594-C94DAB09-6E8B-4AE0-80D2-2B0332102859Q47382454-0FAA4D6C-3C24-4598-9E77-C79FF4003794Q47572441-D255E7BD-37A3-4374-9184-D573E5CBFB40Q48046284-312A57D7-B50B-4B58-BA66-D249281D9630Q48053609-1AA3FB5C-B49E-40AF-94AA-FFECBA984A0AQ48631090-C589603F-EA08-4945-8DF6-F424FFD9D220Q48655930-DE1B766C-4F5C-426D-BF42-761A214C1DECQ51711081-CA66D137-A8CA-428B-92F5-30DEC336FB75Q52653554-0EDA5713-628A-4D16-9647-852C7FDE7E62Q56699962-E01D7208-C36A-4F0A-92E3-7F9C63121A8FQ57695411-49EDCFEE-A228-406A-9D91-91A350E987D3Q60138752-41F2E353-5B0C-4A5E-99F3-203934068D76Q73192498-F29AEAA0-AB88-4E60-8E33-60ECDF3F26FCQ77402312-155E0293-3B16-431C-9E42-AD1798F10773Q79700200-7BE3F011-47CB-4E33-931E-F634879BF1B6Q79853462-AF403A8F-EEAF-4E2B-A4EB-C6B9A0CA2ED6Q81330534-9CCFB013-B6E4-44CE-B447-054E049DD837Q83155710-8DE6A8C8-9DE4-44F5-B895-C0CBE669A895Q86069432-564BDED5-0C67-41AE-8AB5-6CB4DAFAA3DCQ86181614-17BE63C9-C95C-4C20-AD89-5F52C8E156A7Q86640562-33DF7A55-D280-44F2-9579-A61E9F46D58BQ87373433-CDE145E6-DB24-495B-B5A7-CADCE6A65D7E
P50
description
researcher ORCID ID = 0000-0001-5211-5334
@en
wetenschapper
@nl
name
Mark K Su
@ast
Mark K Su
@en
Mark K Su
@es
Mark K Su
@nl
type
label
Mark K Su
@ast
Mark K Su
@en
Mark K Su
@es
Mark K Su
@nl
prefLabel
Mark K Su
@ast
Mark K Su
@en
Mark K Su
@es
Mark K Su
@nl
P31
P496
0000-0001-5211-5334